We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$670M
AUM Growth
+$109M
Cap. Flow
+$144M
Cap. Flow %
21.49%
Top 10 Hldgs %
59.4%
Holding
184
New
14
Increased
76
Reduced
55
Closed
39

Top Buys

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$71.8M
2
WPZ
Williams Partners L.P.
WPZ
+$17.8M
3
BPL
Buckeye Partners, L.P.
BPL
+$15M
4
EPD icon
Enterprise Products Partners
EPD
+$13.8M
5
ET icon
Energy Transfer Partners
ET
+$13.6M

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners L.p.
ETP
+$45.5M
2
SHV icon
iShares 0-1 Year Treasury Bond ETF
SHV
+$34.1M
3
MPC icon
Marathon Petroleum
MPC
+$6.13M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$4.81M
5
SSO icon
ProShares Ultra S&P500
SSO
+$4.67M

Sector Composition

Rank Sector Weight
1 Energy 73.91%
2 Healthcare 7.71%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
126
Prothena Corp
PRTA
$447M
$297K 0.04%
5,494
+191
+4% +$10.2K
CBIO
127
Crescent Biopharma
CBIO
$629M
$294K 0.04%
+263
New +$217K
INO icon
128
Inovio Pharmaceuticals
INO
$83.9M
$294K 0.04%
3,122
-239
-7% -$20.4K
KPTI icon
129
Karyopharm Therapeutics
KPTI
$161M
$294K 0.04%
2,167
+143
+7% +$21.2K
GBT
130
DELISTED
Global Blood Therapeutics, Inc.
GBT
$294K 0.04%
10,761
-6,624
-38% -$197K
MGNX icon
131
MacroGenics
MGNX
$255M
$293K 0.04%
16,761
+2,633
+19% +$50.2K
TTPH
132
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$292K 0.04%
+2,044
New +$316K
LXRX icon
133
Lexicon Pharmaceuticals
LXRX
$1.02B
$291K 0.04%
17,691
-459
-3% -$7.11K
BCRX icon
134
BioCryst Pharmaceuticals
BCRX
$2.38B
$287K 0.04%
51,671
+783
+2% +$4.77K
BLUE
135
DELISTED
bluebird bio
BLUE
$281K 0.04%
207
-106
-34% -$128K
MYOK
136
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$280K 0.04%
21,407
+521
+2% +$6.87K
NERV icon
137
Minerva Neurosciences
NERV
$207M
$275K 0.04%
3,882
+1,281
+49% +$82.9K
TGTX icon
138
TG Therapeutics
TGTX
$8.5B
$269K 0.04%
26,759
-29,783
-53% -$333K
TVRD
139
Tvardi Therapeutics
TVRD
$24M
$264K 0.04%
477
-423
-47% -$268K
JNCE
140
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$259K 0.04%
+18,442
New +$395K
CYTK icon
141
Cytokinetics
CYTK
$11.1B
$257K 0.04%
21,255
-3,624
-15% -$50.4K
UPW icon
142
ProShares Ultra Utilities
UPW
$18.8M
$257K 0.04%
22,852
+10,452
+84% +$120K
FHLC icon
143
Fidelity MSCI Health Care Index ETF
FHLC
$3.25B
$147K 0.02%
3,829
-7,071
-65% -$259K
VAW icon
144
Vanguard Materials ETF
VAW
$2.96B
$143K 0.02%
+1,175
New +$141K
SPY icon
145
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
$85K 0.01%
+1,050
New +$252K
CMS icon
146
CMS Energy
CMS
$22.9B
– –
-14,408
Closed -$645K
CWB icon
147
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.74B
– –
-24,056
Closed -$1.16M
DEM icon
148
WisdomTree Emerging Markets High Dividend Fund
DEM
$3.89B
– –
-19,031
Closed -$777K
DTE icon
149
DTE Energy
DTE
$30.8B
– –
-7,914
Closed -$688K
EIX icon
150
Edison International
EIX
$30.6B
– –
-14,275
Closed -$1.14M
4 5
6
7 8

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
OC
Optima Capital Beaverton, Oregon $215M AUM 17.28% 1-Year Est. Return
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return

Virtus ETF Advisers's Q2 2017 Portfolio in Review

As of Q2 2017, Virtus ETF Advisers held 184 positions worth $670M, up 19% from $562M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Virtus ETF Advisers deployed $144M of net new capital in Q2 2017, opening 14 new positions and adding to 76 existing holdings. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.

By sector, the portfolio is most concentrated in Energy at 74% of assets, up from 70% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Marathon Petroleum, an estimated $6.13M trimmed.

  • Virtus ETF Advisers's largest Q2 2017 buy was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
  • Virtus ETF Advisers added most to Energy Transfer Partners, L.P. in Q2 2017, an estimated $71.8M increase.
  • Virtus ETF Advisers's biggest Q2 2017 reduction was Marathon Petroleum, cutting an estimated $6.13M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $45.5M.
  • Virtus ETF Advisers's ten largest holdings make up 59% of its $670M portfolio in Q2 2017.
  • Virtus ETF Advisers opened 14 new positions and closed 39 in Q2 2017.
  • Virtus ETF Advisers's portfolio value rose 19% quarter-over-quarter to $670M.

Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.